Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Dompé Farmaceutici S P A has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, meaning that every pending matter is being reviewed by a different person. This variety in examiners provides the company with multiple points of feedback within the USPTO.
The portfolio is active across 3 distinct art units. This indicates that while the technology area is Biotechnology & Pharmaceuticals, the specific applications are categorized into three different specialized groups. BORI, IBRAHIM D is the busiest examiner for the company, currently overseeing 1 busiest examiner pending office action.
With 5 pending office actions and 5 distinct examiners, the prosecution workload is perfectly distributed. No single examiner holds more than one busiest examiner pending office action. Practitioners must navigate the requirements of 3 distinct art units, which may involve different examination cultures or timelines for the active applications.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794935 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | MARTINEZ, TARA L | 2d overdue |
| 18564953 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | CHO, DAVID H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16873803 | GROWTH FACTOR OTIC FORMULATIONS | KATAKAM, SUDHAKAR | 25d overdue |
| 17794935 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | MARTINEZ, TARA L | 2d overdue |
| 18918219 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | BORI, IBRAHIM D | — |
| 18564953 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | CHO, DAVID H | — |
| 18267739 | BDNF OTIC FORMULATIONS AND USE THEREOF | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1693 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18918219 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | BORI, IBRAHIM D | — | §102§103§112DP | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18564953 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | CHO, DAVID H | 1693 | §102§103 | Final Rejection | — | Pending | Nov 28, 2023 |
| 18267739 | BDNF OTIC FORMULATIONS AND USE THEREOF | DABKOWSKI, ERINNE R | 1654 | §102§103DP | Final Rejection | — | Pending | Jun 15, 2023 |
| 17794935 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | MARTINEZ, TARA L | 1654 | §103§112Other | Final Rejection | 2d overdue | Pending | Jul 22, 2022 |
| 16873803 | GROWTH FACTOR OTIC FORMULATIONS | KATAKAM, SUDHAKAR | 1658 | §103Other | Non-Final OA | 25d overdue | Pending | Jul 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial